AMGN · News · 20260910N
Product Pipeline Progress
AMGEN INC · 2026-09-10 · Importance 34 · Surprise 42 · In source text
Amgen and AstraZeneca reported survival benefits for the Imdelltra-Imfinzi combination in first-line extensive-stage small-cell lung cancer. The results could support broader use of Imdelltra beyond its current treatment setting. Imdelltra was also cited in reporting on positive Phase 3 trial results, providing additional clinical support for the product pipeline.
Key facts
- The HSBC note mentioned a regulatory setback for a rare-disease drug affecting Amgen. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | contingent | — | The HSBC note mentioned a regulatory setback for a rare-disease drug affecting Amgen. |